Before 2009, the third-party inspection industry developed slowly, one of the main reasons being the high policy barriers of the country. Since the implementation of the public hospital reform program, the state has gradually liberalized the third-party inspection industry. In the United States and Europe, third-party laboratories have become the mainstream and mature business model in the diagnostic market, accounting for about 40% of the in vitro diagnostic market, with an annual growth rate of about 5%. The third-party inspection of this industry, which is only 20 years old, has grown by about 30% in the country and may grow at a rate of 20%-25% in the next five years. The ICL industry has a scale of about 7 billion yuan. The Independent Clinical Laboratory (ICL) is also a third-party medical testing platform. It establishes business partnerships with medical institutions, collects and tests the specimens collected by these institutions, and returns the test results for clinical application. The product of specialized division of medical services, they are juxtaposed with the laboratory and pathology department of the hospital, and are in the middle of the diagnostic industry chain. The upstream of the medical diagnostic industry chain is the manufacturer of IVD equipment and reagents. The number of domestic IVD manufacturers exceeded 600 at the end of 2014, but the market concentration is low, with Mindray, Kehua Bio and Meikang Bio as the leading. Downstream of the medical diagnosis industry chain is a hospital-based medical institution. Different levels of medical institutions are willing to cooperate with independent laboratories under the promotion of grading diagnosis and treatment policies. The middle reaches of the medical diagnosis industry chain is the medical laboratory, which can be divided into hospital internal laboratories, independent medical laboratories (ICL) and clinic attached laboratories. The number of enterprises that have carried out ICL business in 2015 has grown to 356, according to their income calculation. The industry scale is about 7 billion yuan, and the compound annual growth rate is between 30-50%. The current industry is in a state of expansion of the staking. Among them, the gold field test, Dean diagnosis, Daan gene market share is about 32%, 16%, 4%, accounting for more than half of the industry. Compared with the hospital laboratory, the ICL has a strong bargaining power and a large sample size, which can effectively reduce the cost of a single test, and has a significant scale effect; and if ICL works with several hospitals at the same time, it can promote mutual recognition of test results. Reduce the repeated examination of patients and help the implementation of graded diagnosis and treatment. ICL penetration rate is less than 3%, and the future space is broad. In 2015, the income of medical institutions in China was 337.5 billion yuan. According to industry experience, the inspection income accounted for 8%-10% of the medical institution's business income. It can be inferred that in 2015, China's medical inspection market was about 270-375 billion. According to the data of the past ten years, the compound growth rate of the medical inspection market in China is 15%, and the scale of the medical inspection market in 2020 is about 5430-6679 billion yuan. According to the income of domestic ICL companies, the independent medical laboratory market reached a scale of about 7 billion in 2015. It can be inferred that the proportion of independent medical laboratories in the medical testing market in 2015 was about 2.1%-2.6%, and the US inspection market. There is a big gap in the penetration rate of 38%. Driven by the continuous strengthening of grassroots medical institutions, the maturity of molecular diagnostics, the cost of medical insurance, the development of private hospitals, and the reduction of the price of inspection projects, it is assumed that the proportion of independent laboratories in the medical inspection market will reach 8% in 2020, then 2020. The annual independent laboratory market can reach 43-543 billion yuan, compared with 6-8 times the current growth space.
We're Professional Supplier Extract Powder manufacturers and suppliers in China specialized in providing high-quality products at low price. We warmly welcome you to buy or wholesale bulk Supplier Extract Powder for sale here from our factory. For a free sample, contact us now.
Supplier Extract Powder,Supplier Extract ,Supplier Powder Manufacturer in China Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.kangnewpharmas.com